Challenge of Surrogate Endpoints

被引：3

作者：

Furgerson, James L. ^{[1
]}

Hannah, William N., Jr. ^{[1
]}

Thompson, Jennifer C. ^{[1
]}

机构：

[1] Brooke Army Med Ctr, MCHE MED Cardiol Serv, Dept Med, Ft Sam Houston, TX 78234 USA

来源：

SOUTHERN MEDICAL JOURNAL | 2012年 / 105卷 / 03期

关键词：

biomarkers; clinical endpoint; intermediate endpoint; surrogate endpoint; DENSITY-LIPOPROTEIN CHOLESTEROL; HUMAN ATHEROSCLEROTIC LESIONS; ESTROGEN PLUS PROGESTIN; CORONARY-HEART-DISEASE; RISK-FACTOR; FOLIC-ACID; PLASMA HOMOCYSTEINE; CARDIOVASCULAR-DISEASE; SECONDARY PREVENTION; VASCULAR-DISEASE;

D O I：

10.1097/SMJ.0b013e318249891e

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Surrogate endpoints are biomarkers that are intended to substitute for clinical endpoints. They have been used to find novel therapeutic targets, improve the statistical power and shorten the duration of clinical trials, and control the cost of conducting research studies. The more generalized use of surrogate endpoints in clinical decision making can be hazardous and should be undertaken with great caution. This article reviews prior work with surrogate endpoints and highlights caveats and lessons learned from studies using surrogate endpoints.

引用

页码：156 / 160

页数：5

共 50 条

[21] Information recovery in a study with surrogate endpoints
Chen, SX
Leung, DHY
Qin, J
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 2003, 98 (464) : 1052 - 1062
[22] Evaluating Candidate Principal Surrogate Endpoints
Gilbert, Peter B.
Hudgens, Michael G.
BIOMETRICS, 2008, 64 (04) : 1146 - 1154
[23] Surrogate Endpoints in Localized Prostate Cancer
Hartman, Holly E.
Jackson, William C.
CANCER JOURNAL, 2020, 26 (01): : 48 - 52
[24] Principles of use of surrogate markers and endpoints
Kluft, C
MATURITAS, 2004, 47 (04) : 293 - 298
[25] Validation of surrogate endpoints in digestive oncology
Methy, N.
Bedenne, L.
Bonnetain, F.
BULLETIN DU CANCER, 2009, 96 (05) : 591 - 595
[26] SURROGATE ENDPOINTS IN ONCOLOGY DRUG DEVELOPMENT
Li, Nicole F.
ANNALS OF ONCOLOGY, 2014, 25
[27] SURROGATE ENDPOINTS IN CLINICAL-TRIALS
FRIEDMAN, L
YUSUF, S
CONTROLLED CLINICAL TRIALS, 1985, 6 (03): : 222 - 222
[28] Surrogate endpoints in cancer drug development
Sikora, K
DRUG DISCOVERY TODAY, 2002, 7 (18) : 951 - 956
[29] Surrogate endpoints: Wishful thinking or reality?
Baker, Stuart G.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (08): : 502 - 503
[30] Surrogate Efficacy Endpoints in Oncology Trials
Maurie Markman
Pharmaceutical Medicine, 2009, 23 (5-6) : 283 - 287

← 1 2 3 4 5 →